Interferons at age 50: past, current and future impact on biomedicine. - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Nature Reviews Drug Discovery Année : 2007

Interferons at age 50: past, current and future impact on biomedicine.

Ernest C Borden
  • Fonction : Auteur
Ganes C Sen
  • Fonction : Auteur
Robert H Silverman
  • Fonction : Auteur
Richard M Ransohoff
  • Fonction : Auteur
Graham R Foster
  • Fonction : Auteur
George R Stark
  • Fonction : Auteur

Résumé

The family of interferon (IFN) proteins has now more than reached the potential envisioned by early discovering virologists: IFNs are not only antivirals with a spectrum of clinical effectiveness against both RNA and DNA viruses, but are also the prototypic biological response modifiers for oncology, and show effectiveness in suppressing manifestations of multiple sclerosis. Studies of IFNs have resulted in fundamental insights into cellular signalling mechanisms, gene transcription and innate and acquired immunity. Further elucidation of the multitude of IFN-induced genes, as well as drug development strategies targeting IFN production via the activation of the Toll-like receptors (TLRs), will almost certainly lead to newer and more efficacious therapeutics. Our goal is to offer a molecular and clinical perspective that will enable IFNs or their TLR agonist inducers to reach their full clinical potential.

Dates et versions

hal-00203077 , version 1 (08-01-2008)

Identifiants

Citer

Ernest C Borden, Ganes C Sen, Gilles Uze, Robert H Silverman, Richard M Ransohoff, et al.. Interferons at age 50: past, current and future impact on biomedicine.. Nature Reviews Drug Discovery, 2007, 6 (12), pp.975-90. ⟨10.1038/nrd2422⟩. ⟨hal-00203077⟩
75 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More